Search results
Results from the WOW.Com Content Network
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. [3] [4] It is taken by mouth. [3] [4] Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from ...
[41] c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, [16] as is neurofibromatosis-1-associated wild-type GIST. [36] A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. [36] [42] Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. [43]
Trifluridine/tipiracil (FTD–TPI), sold under the brand name Lonsurf, is a fixed-dose combination medication that is used as a third- or fourth-line treatment of metastatic colorectal cancer or gastric cancer, after chemotherapy and targeted therapeutics have failed.
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. It is also used for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth ...
Stomach cancer, also known as gastric cancer, is a malignant tumor of the stomach. It's a cancer that develops from the lining of the stomach. [10] Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. [2]
The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed.
From January 2011 to May 2011, if you bought shares in companies when Jon F. Hanson joined the board, and sold them when he left, you would have a 4.6 percent return on your investment, compared to a 7.0 percent return from the S&P 500.
Chemotherapy can boost tumor immunity in two main ways: (a) by killing cancer cells through immunogenic cell death, and (b) by affecting both cancerous and normal cells in the tumor environment. Despite this, many chemotherapy treatments can also suppress the immune system by causing lymphopenia or impairing lymphocyte function.